GlassScriptPhysician profile
Michael Cuong Luu
NPI 1235244146
$22,424.78
in general payments reported to CMS, 2019-2025
37 companies · $4,180 in 2025
The $4,180 reported for 2025 was more than what 86% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,656 · 2020: $1,709 · 2021: $2,881 · 2022: $4,103 · 2023: $2,951 · 2024: $3,944 · 2025: $4,180.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Travel and Lodging: $203 · Education: $172.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,700.27 |
| Travel and Lodging | $202.96 |
| Education | $171.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,749.88 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $3,668.31 | 2019-2025 | Ofev, Stiolto Respimat, Jascayd |
| Glaxosmithkline, LLC. | $3,300.81 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Actelion Pharmaceuticals US, INC. | $1,773.99 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Regeneron Healthcare Solutions, INC. | $909.52 | 2019-2025 | Dupixent |
| Mylan Specialty L.P. | $884.54 | 2019-2024 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $800.13 | 2019-2025 | |
| Genzyme Corporation | $667.38 | 2019-2025 | |
| Electromed, INC. | $533.46 | 2021-2025 | Smartvest |
| Baxter Healthcare | $525.08 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Monarch Airway Clearance System, Hillrom - Life 2000 Ventilation System |
| Philips North America LLC | $441.14 | 2019-2025 | Vest Therapy Und, (O58) Sleep Respiratory Care Und |
| Sunovion Pharmaceuticals INC. | $422.40 | 2019-2021 | |
| Amgen INC. | $386.93 | 2022-2025 | Tezspire |
| Advanced Respiratory, INC | $369.60 | 2020-2021 | |
| Nalu Medical, INC. | $365.25 | 2024-2025 | Nalu Neurostimulation System |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $350.39 | 2025 | Acthar |
| United Therapeutics Corporation | $322.39 | 2021-2024 | Tyvaso |
| Verona Pharma, INC. | $287.04 | 2025 | Ohtuvayre |
| Grifols USA, LLC | $225.75 | 2019-2023 | Prolastin-C Liquid |
| Viatris Specialty LLC | $217.61 | 2025 | Yupelri |
| Merck Sharp & Dohme LLC | $211.05 | 2021-2024 | Winrevair |
| Genentech USA, INC. | $180.99 | 2019-2023 | Xolair |
| Boston Scientific Corporation | $144.02 | 2025 | General - Pain Management, General - Therapies |
| Takeda Pharmaceuticals U.S.A., INC. | $127.21 | 2020-2023 | Glassia |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $115.14 | 2019 | |
| Covis Pharma Gmbh | $95.62 | 2020-2022 | |
| Phadia US INC. | $79.91 | 2022-2024 | Immunocap |
| Sanofi-Aventis U.S. LLC | $78.99 | 2025 | |
| Circassia INC. | $54.29 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $27.85 | 2019-2022 | |
| Abbvie INC. | $25.66 | 2025 | |
| Pfizer INC. | $22.29 | 2023 | |
| Abbott Laboratories | $21.64 | 2024 | Eterna |
| Insmed, INC. | $19.25 | 2025 | Arikayce |
| Monaghan Medical Corporation | $13.20 | 2023 | Aeroeclipse |
| Spr Therapeutics, INC | $3.18 | 2025 | Sprint Pns System |
| Janssen Pharmaceuticals, INC | $2.89 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Luu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.